Updated results from the SPARK phase II cohort indicate responses to the combination of sitravatinib, a tyrosine-kinase inhibitor, with tislelizumab, an anti–PD-1 antibody, in patients with locally recurrent or metastatic triple-negative breast cancer (TNBC). The single-arm multi-cohort trial measured objective responses and safety signals, reporting activity in a difficult-to-treat population. The investigators highlighted cohort-level response rates and durability metrics that could justify randomized testing. Sponsors and oncology groups will assess whether the combination merits registration-directed development or biomarker-driven follow-up studies.